Close

Novartis' Sandoz unit receives EC approval

News
Typography

Sandoz, a Novartis division and the global leader in biosimilars, announced that the European Commission (EC) has approved a type II variation for the addition of a subcutaneous (s.c.) route of administration in Binocrit's® (epoetin alfa) nephrology indication.

Carol Lynch, Global Head Biopharmaceuticals, Sandoz said, By expanding our biosimilar offering to the healthcare community, the EC approval of a subcutaneous route of administration for use in our Binocrit's nephrology indication will mean more choice for healthcare professionals as well as increased convenience for patients.

Subscribe to our Newsletter
captcha 
Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok